MedTrace Logo

Effect on HIV Medications on EPC Cells

NCT03782142 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2022-03-22

No results posted yet for this study

Summary

This is a 3 arm, non-Interventional pilot single time point cross sectional study for the duration of 1 year. Total of 30 candidates (10 in each Group) will be enrolled into three different groups taking three different Antiretroviral regimen.

Based on current regimens that are commonly used (2017-2018 ART guidelines), our groups will include NRTI such as TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate) plus one of the following:

Group A: an NNRTI (Non-nucleoside reverse transcriptase inhibitor, Rilpivirine Group B a boosted Protease Inhibitor: Prezcobix- \[darunavir+cobicistat combination\] Group C: an Integrase inhibitor (dolutegravir)

Once Informed Consent Process is obtained, blood will be drawn (55 ml) for stem/progenitor cell harvest and 15-20mls for biochemistry analysis. The Investigators will also obtain weight, waist-circumference, BP, pulse, BMI, Tanita body composition scale measures (which gives us body habitus measurements) and arterial stiffness measures.

Conditions

  • AIDS

Interventions

DRUG

Tenofovir

TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)

DRUG

Rilpivirine

NNRTI

DRUG

Prezcobix

PI

DRUG

Dolutegravir

II

Sponsors & Collaborators

  • Sabyasachi Sen

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2020-11-12
Completion
2021-12-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03782142 on ClinicalTrials.gov